Since we previously observed a different distribution of cancer types according to MTAP status with a higher frequency of more aggressive cancer types in the MTAP loss group, this uneven distribution may explain the observed difference in PFS between the two cohorts, rather than the MTAP classification itself. The gene discussed is MTAP; the disease is cancer.